<DOC>
	<DOCNO>NCT01470859</DOCNO>
	<brief_summary>Levodopa non-ergot dopaminergic agonist pramipexole recommend first-line symptomatic treatment early untreated Parkinson 's disease ( PD ) , previous clinical trial indicate initial pramipexole own advantage levodopa regard motor complication , contrary , less adverse effect like freeze severe somnolence favor initial treatment levodopa . Thus , remain controversial initiation medication well patient early PD . Parkinson 's disease-related spatial covariance patter ( PDRP ) new biomarker represent network activity brain severity PD . Based literatures previous data , investigator hypothesize PDRP serve biomarker help u evaluate compare effect levodopa pramipexole progression PD , might able provide evidence clinician address critical issue .</brief_summary>
	<brief_title>The Effect Pramipexole Metabolic Network Activity Compared With Levodopa Early Parkinson 's Disease</brief_title>
	<detailed_description>CALM-PD study find Pramipexole reduce occurrence motor complication compare Levodopa use initiative treatment , still remain debatable initiation medication well patient De Novo PD . PDRP ( Parkinson 's disease-related spatial covariance pattern ) biomarker represent network activity cortico-striato-pallido-thalamocortical pathway highly reproducible stable network activity individual subject . The study publish `` J Neuroscience '' 2010 show abnormal PDRP antecede appearance motor sign 2 year , indicate PDRP might promise biomarker identify PD early stage . Moreover , PDRP able represent progression severity PD well . It report Levodopa reduce PD-related network activity , degree network suppression correlate clinical improvement . However , study currently show impact pramipexole brain PDRP network compare levodopa initiative treatment .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<criteria>idiopathic Parkinson 's disease meeting United Kingdom ( UK ) brain bank criterion De Novo Hoehn &amp; Yahr staging ( H &amp; Y ) III Atypical Parkinsonism Pregnant breastfeed woman abnormal Liver/kidney function participate clinical trial within 30 day enrol trial .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>De Novo parkinson 's disease</keyword>
	<keyword>initial treatment</keyword>
	<keyword>pramipexole</keyword>
	<keyword>Levodopa</keyword>
	<keyword>Parkinson 's disease-related spatial covariance pattern</keyword>
</DOC>